Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children

Vaccine

Volumn 26, Issue 33, 2008, Pages 4210-4217

  Levin, Myron J ^a   Song, Lin Ye ^b   Fenton, Terrence ^b   Nachman, Sharon ^c   Patterson, Julie ^a   Walker, Robert ^d   Kemble, George ^d   Allende, Maria ^d   Hultquist, Micki ^d   Yi, Tingting ^d   Nowak, Barbara ^e   Weinberg, Adriana ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d MEDIMMUNE   (United States)

^e FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

Author keywords

HIV infected children; Live attenuated influenza vaccine; Vaccine virus shedding

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AZITHROMYCIN; CEFTRIAXONE; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; TRIPLE VACCINE;

ABDOMINAL DISEASE; ABDOMINAL PAIN; ADOLESCENT; ANOREXIA; ANTIBODY RESPONSE; ARTICLE; ASTHMA; CELLULITIS; CHILD; CHILL; CONJUNCTIVITIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EAR DISEASE; EPISTAXIS; EYE DISEASE; FATIGUE; FEMALE; FEVER; FOLLICULITIS; HEADACHE; HEMAGGLUTINATION INHIBITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE LUMP; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; LUNG DISEASE; LYMPHADENITIS; MAJOR CLINICAL STUDY; MALAISE; MALE; NASOPHARYNGEAL DISCHARGE; NOSE CONGESTION; OTALGIA; OTITIS MEDIA; PAIN; PHARYNX DISEASE; PNEUMONIA; PRIORITY JOURNAL; RASH; SKIN ABSCESS; SKIN DISEASE; SORE THROAT; THORAX PAIN; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; VIRUS SHEDDING; VOMITING;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HIV INFECTIONS; HUMANS; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; MALE; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VIRUS SHEDDING;

EID: 47149118319     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.05.054     Document Type: Article

References (45)

1. Morishima T., Togashi T., Yogata S., Okuno Y., Miyazaki C., Tashiro M., et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis 35 (2002) 512-517
2. Siberry G.K. Complications of influenza infection in children. Pediatr Ann 209 (2000) 683-690
3. Neuzil K.M., Zhu Y., Griffin M.R., Edwards K.M., Thompson J.M., Tollefson S.J., et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis 185 (2002) 147-152
4. CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immmunization Practices (ACIP). MMWR 53 (No. RR-6) (2004) 1-40
5. Rojo J., Ruiz-Contreras J., Fernandez M., Marin M., and Folgueira I. Influenza-related hospitalizations in children younger than three years of age. Pediatr Infect Dis J 25 (2006) 596-601
6. Poehling K., Edwards K., Weinberg G., Szilagyi P., Staat M.A., Iwane M.K., et al. The underrecognized burden of influenza in your children. N Engl J Med 355 (2006) 31-40
7. Iskander M., Booy S., and Lambert S. The burden of influenza in children. Curr Opin Infect Dis 20 (2007) 259-263
8. Mahdi S.A., Ramasamy N., Bessellar T.G., Saloojee H., and Klugman K.P. Lower respiratory tract infections associated with influenza A and B viruses in an area with a high prevalence of pediatric human immunodeficiency type 1 infection. Pediatr Infect Dis J 21 (2002) 291-297
9. Fine A.D., Bridges C.B., DeGuzman A.M., Glover I., Zeller B., Wong S.J., et al. Influenza A among subjects with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis 32 (2001) 1784-1791
10. Safrin S., Rush J.D., and Mills J. Influenza in patients with human immunodeficiency virus infection. Chest 98 (1990) 33-37
11. Klein M.B., DelBalso L., Coté S., and Boivin G. Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis 45 (2007) 234-240
12. Neuzil K.M., Coffey C.S., Mitchell Jr. E.F., and Griffen M.R. Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection. J Acquir Immune Defic Syndrom 34 (2003) 304-307
13. McFarland EJ. In: Hay Jr WW, Levin MJ, Sondheimer JM, Deterding RR, editors. Human immunodeficiency virus infection in current diagnosis & treatment, 18th ed.; 2007, pp. 1140-1151 [Chapter 37].
14. http://www.cdc.gov/flu/protect/hiv-flu.htm
15. Lyall E.G., Charlett A., Watkins P., and Zambon M. Response to influenza virus vaccination in vertical HIV infection. Arch Dis Child 76 (1997) 215-218
16. Fuller J.D., Craven D.E., Steger K.A., Glover I., Zeller B., Wong S.J., et al. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: Impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis 28 (1999) 541-547
17. Günthard H.F., Wong J.K., Spina C.A., Ignacio C., Kwok S., Christopherson C., et al. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis 181 (2000) 522-531
18. Malispina A., Moir S., Orsega S.M., Vasquez J., Miller N.J., Donoghue E.T., et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis 191 (2005) 1442-1450
19. Tasker S.A., Treanor J.J., Paxton W.B., and Wallace M.R. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 131 (1999) 430-433
20. Tomoda T., Morita H., Kurashige T., and Maassab H.F. Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon-gamma production and local IgA response. Vaccine 13 (1995) 185-190
21. Gorse G.J., Otto E.E., Powers D.C., Chambers G.W., Eickhoff C.S., and Newman F.K. Induction of mucosal antibodies by live aattenuated and inactive influenza vaccines in the chronically ill elderly. J Infect Dis 173 (1996) 285-290
22. Boyce T.G., Gruber W.C., Coleman-Dockery S.D., Sannella E.C., Reed G.W., Wolff M., et al. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine 18 (1999) 82-88
23. Ashkenazi S., Vertruyen A., Aristegui J., Esposito S., McKeith D.D., Klemola T., et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 25 (2006) 870-879
24. Fleming D.M., Crowari P., Wahn U., Klemola T., Schlesinger Y., Langussis A., et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 25 (2006) 860-869
25. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. New Engl J Med 356 (2007) 685-696
26. Belshe R.B., Gruber W.C., Mendelman P.M., Cho I., Reisinger K., Block S.L., et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 136 (2000) 168-175
27. Tam J.S., Capeding M.R.Z., Lum L.C.S., Chotpitayasunondh T., Jiang Z., Huang L.M., et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 26 (2007) 619-628
28. Rhorer J., Dickinson S., Oleka N., Cho I., Ambrose C., and Wittes J. Efficacy in children of live attenuated influenza vaccine: a meta-analysis of 9 randomized clinical trials. Presented at the 48th Annual Meeting of the European Society for Pediatric Research (ESPR). Prague, Czech Republic, October 6-8 (2007)
29. King Jr. J.C., Treanor J., Fast P.E., Wolff M., Yan L., Iacuzio D., et al. Comparison of the safety, vaccine virus shedding, and immungenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 181 (2000) 725-728
30. King Jr. J.C., Fast P.E., Zangwill K.M., Weinberg G.A., Wolff M., Yan L., et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 20 (2001) 1124-1131
31. Dowdle W.N., Kendal A.P., and Noble G.R. Influenza viruses. In: Lenette E.H., and Schmidt N.J. (Eds). Diagnostic procedures for viral, rickettsial and chlamydial infections. 5th ed. (1979), American Public Health Associations, Washington, DC 603-605
32. ® OneStep RT-PCR Kit Handbook. Qiagen, Inc.; May 2002.
33. Chan I.S.F., and Zhang Z. Test based confidence intervals for the difference of two binomial proportions. Biometrics 55 (1999) 1201-1209
34. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., et al. The efficacy of live, attenuated, cold-adapted, trivalent, intranasal influenza vaccine in children. N Engl J Med 338 (1998) 1405-1412
35. Jackson C.R., Vavro C.L., Valentine M.E., Pennington K.N., Lanier E.R., Katz S.L., et al. Effect of influenza immunization on immunologic and virologic characteristics of pediatric patients infected with human immunodeficiency virus. Pediatr Infect Dis J 16 (1997) 200-204
36. Abzug M.J., Pelton S.I., Song L.-Y., Fenton T., Levin M.J., Nachman S.A., et al. Immunogenicity, safety, and predictors of response to a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 25 (2006) 920-929
37. Levin M.J., Gershon A.A., Weinberg A., Blanchard S., Nowak B., Palumbo P., et al. Immunization of HIV-infected children with varicella vaccine. J Pediatr 139 (2001) 305-310
38. Piedra P.A., and Glezen P.W. Influenza in children: epidemiology, immunity and vaccines. Semin Pediatr Infect Dis 2 (1991) 140-146
39. Belshe R., Ambrose C., Walker R.E., Yang C.F., Yi T., Hultquist M., et al. Genetic sequences of circulating 2004-2005 influenza strains and serum antibody responses to LAIV vs. TIV in young children. Joint Meeting of the Pediatric Academic Societies and Asian Society for Pediatric Research. Honolulu, May 2-6 (2008) [abstract #4461.2]
40. Ambrose C.S., Walker R.E., and Connor E.M. Live attenuated influenza vaccine in children. Semin Pediatr Infect Dis 17 (2006) 206-212
41. Edwards K.M., Dupont W.D., Westrich M.K., Belshe R., Newman F., Iacuzio D., et al. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza disease. J Infect Dis 169 (1994) 68-76
42. Treanor J.J., Kotloff K., Betts R.F., Belshe R., Newman F., Iacuzio D., et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18 (1999) 899-906
43. Weinberg A., Gona P., Nachman S.A., Defechereux P., Yogev R., Hughes W., et al. Antibody responses to hepatitis A virus vaccine among HIV-infected children with evidence of immunologic reconstitution on antiretroviral therapy. J Infect Dis 193 (2006) 302-311
44. Block SL, Ambrose CS, Walker RE. Shedding and immunogenicity of live attenuated influenza vaccine in subjects 5-49 years of age. Abstract P47, Vaccine Congress; 9-11 December 2007, Amsterdam, The Netherlands.
45. FluMist Prescribing Information. MedImmune, Inc. Issue date: September 2007.